As of today (2024-06-09), the Trailing Annual Dividend Yield of Inozyme Pharma is 0.00%.
The historical rank and industry rank for Inozyme Pharma's Dividend Yield % or its related term are showing as below:
INZY's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.66 * Ranked among companies with meaningful Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Inozyme Pharma Dividend Yield % Historical Data
The historical data trend for Inozyme Pharma's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Inozyme Pharma's Dividend Yield %
For the Biotechnology subindustry, Inozyme Pharma's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Inozyme Pharma's Dividend Yield % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Inozyme Pharma's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Inozyme Pharma's Dividend Yield % falls into.
Inozyme Pharma Dividend Yield % Calculation
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Thank you for viewing the detailed overview of Inozyme Pharma's Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.
Inozyme Pharma (Inozyme Pharma) Business Description
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
INZY has been successfully added to your 